Clinical trial
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative…
NCT00052572 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00052572 |
|---|---|
| Title | Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders |
| Official title | A Multicenter Phase II Study Of BMS 247550 (Epothilone B Analogue) In Indolent Lymphoproliferative Disorders |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphoma |
| Intervention type | Drug |
| Interventions | ixabepilone |
| Enrollment | 35 |
| Start date | Oct 1, 2002 |
| Completion | Jul 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: